Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
beta-lactam · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Ceftriaxone | DRUG | 1000mg iv daily |
| beta-lactam | DRUG | 750mg iv q 23h for 3-14 days |
Inclusion Criteria: * male or female patients at least 18 years of age; * hospitalization with community-acquired pneumonia or development of pneumonia within 48 hours of being hospitalized for another reason; * fever; * new or increased productive cough; * chest pain, shortness of breath, or rapid...
Beta-lactam is an investigational small molecule being studied for the treatment of bacterial pneumonia in hospitalized patients. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Beta-lactam is being developed by Roche Holding AG, a biopharmaceutical company traded under the ticker RHHBY. The drug is in Phase 2 clinical development for bacterial pneumonia.
Beta-lactam is in Phase 2 clinical development. It is an investigational drug and has not yet been approved for commercial use. A Phase 2 trial has been completed to assess its effects in patients with bacterial pneumonia.
Beta-lactam has one completed Phase 2 clinical trial, identified as NCT00111644. This randomized, double-blind, active-controlled study enrolled 302 hospitalized patients with bacterial pneumonia across multiple countries, including the United States, Argentina, Bulgaria, Chile, Croatia, Hungary, Latvia, Lithuania, Peru, Romania, and Slovakia.
Beta-lactam is a small molecule antibiotic being studied for bacterial pneumonia. It is being developed by Roche Holding AG and is currently in Phase 2 clinical trials. No alternative names for this drug have been disclosed.